IgE plays an important role in allergic asthma. We hypothesized that reducing IgE in the
airway mucosa would reduce airway inflammation. Forty-five patients with mild to moderate …

Immunoglobulin E (IgE) mediates many of the inflammatory processes that underlie the
symptoms of asthma and other allergic respiratory disorders. Recently, a recombinant …

Asthma is a chronic inflammatory disease of the airways in which immunoglobulin E (IgE)
plays a key role by activating a variety of inflammatory cells through interactions with FcɛRI …

Background Patients with severe asthma are often inadequately controlled on existing anti‐
asthma therapy, constituting an unmet clinical need. Objective This randomized, double …

BACKGROUND: Omalizumab is a recombinant monoclonal anti-IgE antibody with proven
efficacy in allergic diseases and further anti-inflammatory potency in the treatment of asthma …

Omalizumab is a humanized monoclonal anti‐IgE antibody developed for the treatment of
allergic disease, with established efficacy in patients with moderate‐to‐severe allergic …

IgE plays a key role in allergic asthma. We investigated whether omalizumab treatment of
patients with moderate to severe allergic asthma leads to changes in inflammatory …

Omalizumab is a humanized monoclonal anti-IgE antibody recently approved for the
treatment of severe allergic asthma. This drug inhibits allergic responses by binding to …

Background While up to 50% of patients with severe asthma have no evidence of allergy,
IgE has been linked to asthma, irrespective of atopic status. Omalizumab, an anti-IgE …

Background: Anti‐IgE, omalizumab, inhibits the allergen response in patients with asthma.
This has not been directly related to changes in inflammatory conditions. We hypothesized …